July 22, 2015 — The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company in its bivalirudin (Angiomax) patent litigation with Hospira Inc.
In its ruling July 2, the Federal Circuit held that U.S. Patent Nos. 7,582,727 (the '727 patent) and 7,598,343 (the '343 patent) are invalid.
On March 31, 2014, the U.S. District Court of Delaware found that all of the asserted claims of the '727 patent and the '343 patent covering Angiomax were valid but not infringed by Hospira's ANDA products. The Medicines Company appealed the District Court's claim construction and non-infringement rulings, while Hospira appealed the validity rulings.
Angiomax is indicated in patients undergoing percutaneous coronary intervention (PCI) with provisional use of GPI and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. In addition, Angiomax is also indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin. Angiomax is not approved for use in patients with acute coronary syndromes (ACS) not undergoing PCI or PTCA.
For more information: www.themedicinescompany.com
November 14, 2025 
